Urachal adenocarcinoma: a rare clinical presentation
Article Sidebar
Main Article Content
Abstract
Urachal tumor is extremely rare, since it is responsible for about 0.01% of all neoplasms already repeated in the history of clinical oncology, with the adenocarcinoma subtype being the most prevalent. Thus, the present work aims to report a case of a 55-year-old patient diagnosed with urachal tumor, relating the clinical presentation of the case according to current literary data. It was possible to show that such a diagnosis, as well as the institution of a standard treatment, is still a clinical challenge in modern medical practice.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Costa TM, Santana RM, Souza AF, et al. Adenocarcinoma de úraco: relato de caso de um tumor incidental. Urominas. 2016;3(7):56-8.
Cruz CLP, Fernandes GL, Natal MRC, et al. Neoplasia de úraco: relato de caso. Radiol. bras. 2014;47(6):387-8. https://doi.org/ 10.1590/ 0100-3984.2013.1879
NeuUro. Tumores de Úraco [Internet]. 2011 [cited 2021 Mar 17]. Available from: http:// neouro.com.br/ tratamentos/ tumores-de-uraco/
García Salazar N, Pérez Silva MM, et al. Carcinoma de úraco, una neoplasia maligna poco frecuente. Rev. méd. Urug. (En línea). 2018;34(1):124-33. http://dx.doi.org/10.29193/rmu.34.1.6
Planelles Gómez J, Olmos Sánchez L, Sánchez Cuallado C, et al. Adenocarcinoma de úraco: presentación de dos casos. Rev. chil. Urol. 2018; 83(1):44-8.
Silva CD, Quinta A, Oliveira M, et al. Carcinoma de úraco. Acta Urológica. 2009;26(2):164.
Hamilou Z, North S, Canil C, et al. Management of urachal cancer: a consensus statement by the Canadian Urological Association and genitourinary medical oncologists of Canada. Can Urol Assoc J. 2020;14(3):E57. doi: 10.5489/cuaj.5946
Sheldon C, Clayman R, González R, et al. Signet-Malignant urachal lesions. J Urol. 1984;131(1):1-8. https://doi.org/10.1016/S0022-5347(17)50167-6
Barrientos SL, Poblete MT. Carcinoma de uraco. Cuad. Cir. 2000; 14:27-32.
Zeman M, Silver E, Akin E. CT and PET Findings for Urachal Adenocarcinoma: A Case Report. Ann Clin Case Rep. 2017; 2:1252.
Kumar N, Khosla D, Kumar R, et al. Urachal carcinoma: Clinicopathological features, treatment and outcome. J Cancer Res Ther. 2014;10(3):571-4.
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) – Bladder Cancer. 2021. [cited 2021 Mar 17]. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx
Wein, AJ, Kavoussi LR, Novick AC, et al. Campbell Walsh Urology. Neuropathic dysfunction of the lower urinary tract. 4th ed. USA: Elsevier Saunders; 2011.
Vogelzang NJ, Scardino PT, Shipley WU, et al. Comprehensive Textbook of Genitourinary Oncology. 3rd ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011.
Koster IM, Cleyndert P, Giard RW. Best cases from the AFIP: urachal carcinoma. Radiographics. 2009; 29(3):939-42. https:// doi.org/ 10.1148/rg.293085152
Peugniez C, Ghoneim T, Leroy X, et al. Les cancers de l’ouraqueUrachal cancers. Bull Cancer. 2013;100(5):509–17. doi: 10.1684/bdc.2013.1718
Siefker-Radtke A. Urachal adenocarcinoma: A clinician’s guide for treatment. Semin Oncol. 2012;39(5):619–24. doi: 10.1053/j.seminoncol.2012.08.011
Jung HA, Sun JM, Park SH, et al. Treatment outcome and relevance of palliative chemotherapy in urachal cancer. Chemotherapy. 2014;60(2):73–80. doi: 10.1159/000368071
Kikuchi M, Kamei S, Morirama Y, et al. Case of urachal cancer treated by neoadjuvant chemotherapy with FOLFOX4 (oxaliplatin, 5-FU and leukovolin). Hinyokika Kiyo. 2008;54(8):557–9. PMID: 18788447
Kume H, Tomita K, Takahashi S, et al. Irinotecan as a new agent for urachal cancer. Urol Int. 2006;76(3):281–2. doi: 10.1159/000091635
Siefker-Radtke AO, Gee J, Shen YU, et al. Multimodality management of urachal carcinoma: The M.D. Anderson Cancer Center experience. J Urol. 2003;169(4):1295–8. doi: 10.1097/ 01.ju.0000054646.49381.01
Galsky MD, Iasonos A, Mironov S, et al. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology. 2007;69(2):255-9. doi: 10.1016/j.urology.2006.10.029
Hong JY, Choi MK, Uhm JE, et al. Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract. Med Oncol. 2009;26(2): 186–92. doi: 10.1007/s12032-008-9106-7
Goss G, Hirte H, Miller WH Jr, et al. A phase 1 study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs. 2005; 23(2):147–55. doi: 10.1007/ s10637-005-5860-y
Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(20):2509–20. doi: 10.1056/ NEJMoa1500596
Ashley RA, Inman BA, Sebo TJ, et al. Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer. 2006;107(4):712-20. https:// doi.org/ 10.1002/cncr.22060
Esteves FP, Pinto AC, Pinto AFC. Urachal adenocarcinoma. Braz J Urol. 2001;27(6):560-2.